EUVIMEDEUVIMED entdecken
KommentarOpen Access

Decondensing cancer immunotherapy

Arup K Chakraborty

Science · 2026

DOI: 10.1126/science.ael3828 ↗

Kurz gefasst

Kommentar in der Zeitschrift Science, 2026. Verfasst von Arup K Chakraborty. Beteiligte Einrichtung: Departments of Chemical Engineering, Physics, and Chemistry, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Ca…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Immunotherapy, Neoplasms, T-Lymphocytes. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A checkpoint inhibitor may switch off T cells in a surprising way

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsImmunotherapyNeoplasmsT-LymphocytesProgrammed Cell Death 1 ReceptorAnimalsHumans

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Departments of Chemical Engineering, Physics, and Chemistry, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Ragon Institute of Massachusetts General Brigham, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Chakraborty, A. K. (2026). Decondensing cancer immunotherapy. Science. https://doi.org/10.1126/science.ael3828

Vancouver

Chakraborty AK. Decondensing cancer immunotherapy. Science. 2026. doi:10.1126/science.ael3828

BibTeX
@article{Chakraborty2026,
  author = {Chakraborty, Arup K},
  title = {Decondensing cancer immunotherapy},
  journal = {Science},
  year = {2026},
  doi = {10.1126/science.ael3828}
}
Kostenlos starten →